Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical study of the drug CF-MEV-107 for the treatment of fistulizing Crohn's disease refractory to conventional therapies

Next Previous
Search
Trial Profile

Clinical study of the drug CF-MEV-107 for the treatment of fistulizing Crohn's disease refractory to conventional therapies

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 24 May 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CF-MEV-107 (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions; First in man; Therapeutic Use

    • Most Recent Events

    • 24 May 2018 New trial record
    • 17 May 2018 According to an ESPERITE media release, this clinical trial will be performed in Italy at Padua University Hospital in collaboration with the Women's and Children's Health Department of the University of Padua.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top